Over the last decades, immune checkpoint inhibitors (ICI) and dual BRAF/MEK inhibition have transformed the treatment landscape for patients with advanced melanoma. However, the availability of two effective treatment strategies for patients with BRAF-mutant advanced melanoma brings about the question of the optimal treatment sequence for patients. This article summarizes the currently available evidence on the efficacy and safety of sequential immunotherapy with targeted therapy in this setting.